Business Context and Reporting Period
Company: The Cooper Companies, Inc. (Cooper)
Filing Type: Form 10-K (Annual Report)
Period Ended: October 31, 2007
Business Overview: Cooper operates two primary business units: CooperVision, Inc. (CVI), a global manufacturer of soft contact lenses, and CooperSurgical, Inc. (CSI), a developer of medical devices for women's healthcare (obstetrics and gynecology). The company is headquartered in Pleasanton, California, and employs approximately 7,600 people.
Key Financial Metrics
| Metric | Fiscal 2007 | Fiscal 2006 | Change |
|---|---|---|---|
| Net Sales | $950.6 million | $859.0 million | +11% |
| Gross Profit | $519.5 million | $526.0 million | -1% |
| Gross Margin | 55% | 61% | -600 bps |
| Operating Income | $45.9 million | $112.9 million | -59% |
| Operating Margin | 5% | 13% | -800 bps |
| Net (Loss) Income | $(11.2) million | $66.2 million | Loss vs. Profit |
| Diluted EPS | $(0.25) | $1.44 | N/A |
| Operating Cash Flow | $134.0 million | $150.5 million | -11% |
| Total Debt | $876.6 million | $742.7 million | +18% |
| Cash & Equivalents | $3.2 million | $8.2 million | -61% |
Material Changes vs. Prior Period
- Profitability Decline: Despite an 11% increase in net sales, operating income dropped 59% to $45.9 million, resulting in a net loss of $11.2 million compared to a net income of $66.2 million in 2006.
- Margin Compression: Gross margin decreased from 61% to 55%. This was driven by a shift in product mix toward lower-margin spherical lenses, production start-up costs for new silicone hydrogel products, and integration expenses related to the Ocular Sciences acquisition.
- Segment Performance:
- CVI: Sales grew 8% to $795.9 million. Growth was driven by single-use and multifocal lenses, though the Americas region saw slowed growth due to market shifts toward silicone hydrogel lenses where competitors currently dominate.
- CSI: Sales grew 24% to $154.8 million, driven by acquisitions (Wallach Surgical, Lone Star Medical) and organic growth in hospital market products.
- Debt Structure: In January 2007, the company refinanced its credit facility, issuing $350 million in 7.125% Senior Notes and establishing a $650 million revolving credit facility. Total debt increased to $876.6 million.
Guidance, Outlook, and Risks
- Outlook: Management expects CVI to continue competing successfully with disposable and specialty lenses. Future growth is tied to the successful ramp-up of silicone hydrogel manufacturing (Biofinity brand) and expansion in Europe and Asia. CSI expects to benefit from demographic trends in the women's healthcare market.
- Capital Expenditures: Expected to be between $160 million and $180 million in fiscal 2008, primarily for expanding silicone hydrogel capacity and IT systems.
- Key Risks:
- Competition: Intense competition in the contact lens market, particularly from larger competitors with greater resources in the silicone hydrogel segment.
- Regulatory: Extensive FDA and foreign regulatory requirements for medical devices; delays in approvals could impact new product launches.
- Integration: Ongoing integration of the Ocular Sciences acquisition involves significant costs and operational risks.
- Legal: Pending securities class action litigation regarding the Ocular merger accounting and financial projections; patent litigation with Bausch & Lomb (ongoing) and CIBA Vision (settled in November 2007 with royalty obligations).
- Supply Chain: Reliance on a single supplier (Asahi) for silicone hydrogel raw materials.
Investor Verification Checklist
- Integration Costs: Verify the timeline and total cost of the Ocular Sciences integration plan, estimated at $50 million total, to assess future earnings impact.
- Silicone Hydrogel Ramp-up: Monitor the manufacturing efficiency and market acceptance of the Biofinity silicone hydrogel lens, as this is critical for future margin recovery.
- Legal Exposure: Track the status of the Levine v. The Cooper Cos. securities class action lawsuit and the Bausch & Lomb patent infringement case.
- Debt Covenants: Review compliance with the new credit facility covenants, specifically the Interest Coverage Ratio (currently 5.90:1) and Total Leverage Ratio (currently 3.48:1).
- Inventory Levels: Assess inventory months-on-hand (5.9 reported, 7.4 adjusted) to ensure no significant obsolescence charges are required for new product lines.